![Friedrich Finckenstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Net worth: 582 862 $ as of 2026-06-29
Presently, Friedrich Graf Finckenstein occupies the position of Chief Medical Officer for Iovance Biotherapeutics, Inc. He previously was Global Head-Oncology Translational Medicine at F. Hoffmann-La Roche Ltd. He received a doctorate from the University of Hamburg.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-04 | 140,111 ( 0.03% ) | 582 862 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-07-17 |
| Companies | Position | End |
|---|---|---|
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 3 |
|---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Hamburg
 University of Hamburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions
